NextCell Pharma (NXTCL.ST) Akcja Kurs

NextCell Pharma AB develops stem cell therapies using a proprietary selection algorithm, focusing on autoimmune diabetes and other autoimmune diseases. The company operates a tissue establishment and biobank as a healthcare provider, commercializing mesenchymal stem cell products. Its primary revenue comes from the development and sale of these stem cell therapies to healthcare institutions and research organizations. The firm's business model centers on R&D for stem cell products, with the tissue establishment and biobank supporting its research activities. NextCell targets healthcare providers and research entities as key customers for its stem cell therapies and biobank services. NextCell Pharma AB's revenue streams are derived from the commercialization of its stem cell therapies, leveraging its proprietary technology for autoimmune disease treatment. The company's focus on mesenchymal stem cell products positions it within the healthcare provider segment, specifically serving institutions requiring advanced cell-based treatments.